Multidrug Resistance 1 (MDR1) 3435C/T Genotyping in Childhood Drug-Resistant Epilepsy

dc.contributor.authorSaygi, Semra
dc.contributor.authorAlehan, Fusun
dc.contributor.authorAtac, Fatma Belgin
dc.contributor.authorErol, Ilknur
dc.contributor.authorVerdi, Hasibe
dc.contributor.authorErdem, Remzi
dc.contributor.orcIDhttps://orcid.org/0000-0002-8522-5078en_US
dc.contributor.orcIDhttps://orcid.org/0000-0001-6868-2165en_US
dc.contributor.orcIDhttps://orcid.org/0000-0002-3530-0463en_US
dc.contributor.orcIDhttps://orcid.org/0000-0003-0591-009Xen_US
dc.contributor.orcIDhttps://orcid.org/0000-0002-7537-2170en_US
dc.contributor.pubmedID23465586en_US
dc.contributor.researcherIDAAB-1203-2021en_US
dc.contributor.researcherIDABG-9966-2020en_US
dc.contributor.researcherIDAAK-4825-2021en_US
dc.contributor.researcherIDABG-9940-2020en_US
dc.date.accessioned2024-03-18T12:44:18Z
dc.date.available2024-03-18T12:44:18Z
dc.date.issued2014
dc.description.abstractIntroduction: A mutation at nucleotide position 3435 in exon 26 of the multidrug resistance 1 (MDR1) gene is the most frequently studied polymorphism in relation to multidrug resistance. However, there are conflicting data as to whether the CC or TT genotype of the 3435C>T polymorphism is associated with drug resistance. Methods and results: We investigated the association between this polymorphism in drug-resistant childhood epilepsy by comparison with drug-responsive patients. In total, 59 patients with drug-resistant epilepsy, defined as having four or more seizures within a 12-month period while using three or more AEDs, 60 children with drug-responsive epilepsy who had remained seizure-free for 12 months on their current AED regimen and 76 healthy children were involved in this study. Genotype frequencies in drug-resistant patients were as follows: 32.2% CC, 44.1% CT, 23.7% TT; in the drug-responsive group: 20.0% CC, 50.0% CT, 30.0% TT; in the control group: 24.3% CC, 50.0% CT, 25.7% TT. Comparison of drug-resistant and drug-responsive patients revealed no significant difference in genotype frequency. The findings of the epilepsy patients were not significantly different from those of the healthy control subjects. Conclusions: Our study does not support any significant association between the MDR1 polymorphism and drug-resistant childhood epilepsy. (C) 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.en_US
dc.identifier.endpage142en_US
dc.identifier.issn0387-7604en_US
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84891633061
dc.identifier.startpage137en_US
dc.identifier.urihttp://hdl.handle.net/11727/11858
dc.identifier.volume36en_US
dc.identifier.wos000330151400007en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.braindev.2013.01.016en_US
dc.relation.journalBRAIN & DEVELOPMENTen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiepileptic drug treatmenten_US
dc.subjectIntractable epilepsyen_US
dc.subjectMDR1 polymorphismen_US
dc.titleMultidrug Resistance 1 (MDR1) 3435C/T Genotyping in Childhood Drug-Resistant Epilepsyen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: